Oregon Health & Science University

Orexigen Therapeutics, Inc.

Imperial Innovations Limited

Nalpropion Pharmaceuticals LLC

Imperial College Innovations Limited

Michael Alexander Cowley

Eckard Weber

Roger D Cone

Andrew A Butler

Stephen Robert Bloom

Malcolm J Low

Caroline Jane Small

Rachel Louise Batterham

Gary Dennis Tollefson

Anthony A McKinney

Mohammad Ali Ghatei

Mohammad Ali Ghatel

Malcolm James Duncan Low

Anthony A Mckinney

Gary Tollefson

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance &#x3b1;-MSH activity.

Compositions for affecting weight loss

Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.

Compositions and methods for increasing insulin sensitivity

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.

Modification of feeding behavior

Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering PYY or an agonist thereof and GLP-1 or an agonist thereof to the subject, simultaneously or sequentially, thereby decreasing the calorie intake of the subject.

Modification of feeding behavior using PYY and GLP-1

Screening methods of use in identifying agents that affect caloric intake, food intake, appetite, and energy expenditure are disclosed herein. These methods are used to identify agents of use in treating obesity, or that can be used to decrease the weight of a subject. These methods can also be used to identify agents of use in treating anorexia or cachexia and can be used to increase appetite and to increase the weight and lean body mass of a subject.

Method for screening for agents that affect food intake

Growing community of inventors

Portland, OR, United States of America

Michael Alexander Cowley